drugset / Trial / NCT00670982
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Phase 2
Completed
29 enrolled
Harold J. Burstein, MD, PhD
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabGenentech, Inc. · collabHartford Hospital · collabLowell General Hospital · collabMassachusetts General Hospital · collabNew Hampshire Oncology-Hematology PA · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the effects of the combination of bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
Timeline
- Start
- 2008-05
- Primary completion
- 2011-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Vinorelbine | Small molecule | — | Intravenous |